Fu Q, Gai X, Ji Z
Department of Surgical Oncology, First Clinical College, Norman Bethune University of Medical Sciences, Changchun.
Zhonghua Zhong Liu Za Zhi. 1996 Sep;18(5):382-4.
To assess the value of surgical treatment followed by adjuvant chemotherapy for localized small-cell lung cancer (SCLC), the results of treatment in 86 SCLC patients since 1990 were reviewed. Of 86 patients, 19 patients received pneumonectomy, 53 lobectomy, 6 wedge resection and 8 segmental resection. Postoperative pathologic staging revealed 24 in stage I, 36 in stage II, and 26 in stage III. Postoperative adjuvant chemotherapy was given in 78 patients. Until the latest follow-up, 28 patients remained alive and 58 patients died. The 5-year survival rate of the 86 patients was 37%. The survival of patients in stage I was better than that of patients in stage II (P = 0.018) and stage III (P = 0.021), but the survival of patients in stage II was not significantly different from that of patients in stage III (P = 0.234). In summary, surgical treatment followed by chemotherapy improves significantly the survival of patients with localized SCLC. TNM staging is of prognostic importance.
为评估手术治疗联合辅助化疗对局限性小细胞肺癌（SCLC）的价值，回顾了自1990年以来86例SCLC患者的治疗结果。86例患者中，19例行肺切除术，53例行肺叶切除术，6例行楔形切除术，8例行节段性切除术。术后病理分期显示，Ⅰ期24例，Ⅱ期36例，Ⅲ期26例。78例患者接受了术后辅助化疗。至最新随访时，28例患者存活，58例患者死亡。86例患者的5年生存率为37%。Ⅰ期患者的生存率优于Ⅱ期（P = 0.018）和Ⅲ期（P = 0.021）患者，但Ⅱ期患者的生存率与Ⅲ期患者无显著差异（P = 0.234）。总之，手术治疗联合化疗可显著提高局限性SCLC患者的生存率。TNM分期具有预后意义。
